SCHEMBL1086743

SCHEMBL1086743

CCOC(=O)c1ccc(NC(=O)N2CCC3(CC2)CN(Cc2ccc4ccccc4c2)C(=O)O3)cc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.51
RAB9A P51151 4/20 0.49
ALDH1A1 P00352 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
NPC1 O15118 3/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 3/20 0.47
FAAH O00519 3/20 0.46
TP53 P04637 1/20 0.46
POLB P06746 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
P2RY12 Q9H244 1/20 0.46
KDM4E B2RXH2 1/20 0.45
HTT P42858 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MAOA P21397 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1086533 0.88 FAAH (0.55) MAPK1ALDH1A1SMN1; SMN2MAPTFAAH
SCHEMBL1086597 0.82 MAPT (0.49) MAPK1RAB9AALDH1A1NPC1MAPT
SCHEMBL1086439 0.78 MAPK1 (0.48) MAPK1ALDH1A1SMN1; SMN2MAPTFAAH
SCHEMBL1086470 0.78 FAAH (0.42) FAAHMEN1KMT2A
SCHEMBL12184536 0.78 MAPT (0.51) RAB9AALDH1A1SMN1; SMN2NPC1MAPT
SCHEMBL4486191 0.77 MMP13 (0.40) FAAHKMT2A
SCHEMBL4258569 0.76 MMP1 (0.43) RAB9ANPC1FAAHPOLBMEN1
SCHEMBL1086247 0.76 GPR119 (0.45)
SCHEMBL1086484 0.75 MAPT (0.45) MAPK1RAB9AALDH1A1SMN1; SMN2NPC1
SCHEMBL4486194 0.75 TACR2 (0.41) FAAHKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153795-B2 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs GRUENENTHAL GMBH (DE) 2012-04-10 US claimed
EP-1910381-B1 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2009-06-03 EP claimed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US claimed
US-8153795-B2 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs GRUENENTHAL GMBH (DE) 2012-04-10 US disclosed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs DDO, DAO, OTC MAPK1 2787/4885RAB9A 4568/4885ALDH1A1 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.